๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

Book ID
117791704
Publisher
The Lancet
Year
2011
Tongue
English
Weight
276 KB
Volume
11
Category
Article
ISSN
1473-3099

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Switching to coformulated elvitegravir,
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
โœ Pozniak, Anton; Markowitz, Martin; Mills, Anthony; Stellbrink, Hans-Juergen; Ant ๐Ÿ“‚ Article ๐Ÿ“… 2014 ๐Ÿ› The Lancet ๐ŸŒ English โš– 274 KB